Exploring the Association between Cathepsin B and Parkinson's Disease

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Parkinson's Disease (PD) is a progressive neurodegenerative disorder with complex etiology.
• Cathepsin B, a cysteine protease, has been implicated in various cellular processes, including protein degradation and inflammation.
• N-acetylaspartate is a major metabolite in the central nervous system, primarily found in neurons.

Purpose of the Study:

• To investigate the potential association between Cathepsin B and Parkinson's Disease (PD).
• To explore the role of N-acetylaspartate as a potential mediator in the relationship between Cathepsin B and PD.

Main Methods:

• Utilized summary-level data from Genome-Wide Association Studies (GWAS).
• Employed a two-sample Mendelian randomization (MR) analysis to assess the causal relationship between Cathepsin B and PD.
• Applied a sequential two-step MR approach to investigate the mediation effect of N-acetylaspartate.

Main Results:

• Genetically predicted elevated Cathepsin B levels were associated with a reduced risk of developing PD (OR: 0.9171, p=0.0133).
• No significant evidence was found to suggest that PD affects Cathepsin B levels (OR: 1.0035, p=0.8567).
• The estimated mediation effect of N-acetylaspartate was 7.52% (95% CI: -3.65% to 18.69%).

Conclusions:

• Elevated Cathepsin B levels may confer a protective effect against Parkinson's Disease.
• N-acetylaspartate may play a mediating role in this association.
• Further investigation is warranted to elucidate the precise mechanisms underlying this relationship.